

14 June, 2016

BERMIG Carsten

Cabinet of Commissioner Elzbieta BIENKOWSKA –
Internal Market, Industry, Entrepreneurship and SMEs
Rue de la Loi / Wetstraat 200
1049 Brussels, Belgium

Regarding: Publication of Interest on EDCs

Dear Mr. Bermig and

On behalf of the Endocrine Society's Endocrine Disrupting Chemicals Task Force, and following from our communication from April 25, I would like to take this opportunity to provide some new information in advance of the Commission's pending decision on EDC criteria. Today a new paper was published in the peer-reviewed scientific journal *The Lancet Diabetes and Endocrinology*, by members of the Endocrine Society. The authors include 9 international experts in the field who have been engaged in global efforts to identify science-based criteria for regulation of EDCs.

Along with the commentary in *Environmental Health Perspectives* that we sent on April 25, we believe that this paper could be of relevance to the European Commission in establishing scientific criteria for the identification of Endocrine Disruptors in the context of the PPPR and BPR and in efficiently protecting public health.

It provides further support for our position that the Roadmap Option 3 represents the best option for criteria to identify EDCs based on the widely-accepted WHO/IPCS definition. The paper shows that the simple logic used for the identification and regulation of carcinogens can be used for EDCs. Adding concepts such as that of "potency" or irreversibility would not be scientifically relevant for the selection of criteria to identify EDCs.

We have attached a copy of the manuscript to this letter, and we appreciate your continued attention to this important issue. We look forward to further engagement on EDCs and other critical public health issues.

Sincerely,

Liège University Hospital, Belgium

2055 L Street NW
Suite 600
Washington, DC
20036

T.
F. .

endocrine.org